Strides' cough drug receives USFDA approval
03 August 2015 | News | By BioSpectrum Bureau
Strides' cough drug receives USFDA approval
(Photo Courtesy: www.livewellnewyork.com)
Bangalore-based pharma company Strides Arcolab announced that it has received approval from the United States Food & Drug Administration (USFDA) for Benzonatate Capsules USP, 100 mg and 200 mg.
Benzonatate is used to treat coughs caused by the common cold and other breathing problems (for example, pneumonia, bronchitis, emphysema, and asthma).
It works by reducing the reflex in the lungs that causes the urge to cough.
According to IMS data, the US market for Benzonatate is approximately US $41 million.
The product will be manufactured at the company's oral dosage facility at Bangalore, and marketed by Strides in the US Market.
The product will be launched immediately, said the company in a statement.
